Degree in veterinary medicine, Oporto University; a post-graduation in soft tissues surgery –
Lusofona University, and is currently (2021-2024) a Ph.D. student, in Human Kinetics – Évora
University, Portugal. Involvement in advocacy in rare bone conditions started after
becoming mother of a child with achondroplasia in 2012. Founder and president of ANDO
Portugal, the Skeletal Dysplasia National Association; member of the Committee for Orphan
Medicinal Products (COMP) at the European Medicine Agency; European Patient Advocacy
groups (ePAG) representative at the European Reference Network for Rare Bone diseases –
ERN BOND; co-leader of the Patient Outcomes at the European Registry for Rare bone and
Mineral conditions (EuRR-Bone); EUPATI fellow and EUPATI Portugal vice-President; founder
and first chair of the European Rare Bone Forum (ERBF); co-leader of the Translational
Outreach working group of GEMSTONE COST action; member of EURORDIS E-rare and Rare
2030 expert panel and patient representative expert at EMA and IMI. One of main interests
is translational research in skeletal dysplasias.
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. See more at www.cost.eu.
